Charles Schwab Investment Management Inc Relmada Therapeutics, Inc. Put Options Transaction History
Charles Schwab Investment Management Inc
- $521 Billion
- Q1 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding RLMD
# of Institutions
50Shares Held
6.43MCall Options Held
0Put Options Held
0-
Acadian Asset Management LLC Boston, MA1.23MShares$699,9180.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.21MShares$688,6020.0% of portfolio
-
Black Rock Inc. New York, NY573KShares$326,7880.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA495KShares$282,2330.03% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD397KShares$226,0120.04% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $16.3M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...